[3H]PK11195 binding sites in human neutrophils: effect of fMLP stimulation and modulation in rheumatic diseases

Laura Giusti1, Laura Betti, Gino Giannaccini

  • 1Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Pisa, Italy.

Clinical Biochemistry
|December 17, 2003
PubMed
Abstract

Insights

Peripheral-type benzodiazepine receptor (PBR) binding is modulated by N-formylmethionine-leucine-phenylalanine (fMLP) stimulation in human neutrophils. Psoriatic arthritis patients exhibit increased PBR in neutrophil membranes.

Area of Science:

  • Immunology
  • Pharmacology
  • Cell Biology

Background:

  • Peripheral-type benzodiazepine receptor (PBR) is implicated in inflammatory processes.
  • Neutrophils play a key role in acute inflammation and immune responses.
  • Alterations in PBR may be associated with inflammatory arthritis.

Purpose of the Study:

  • To evaluate [3H]PK11195 binding parameters in N-formylmethionine-leucine-phenylalanine (fMLP)-stimulated neutrophil membranes.
  • To investigate PBR characteristics in neutrophil membranes of patients with osteoarthritis (OA), rheumatoid arthritis (RA), and psoriatic arthritis (PA).

Main Methods:

  • Neutrophils were isolated from patients with OA, RA, PA, and healthy volunteers.
  • fMLP stimulation was performed on neutrophils from healthy individuals.
  • [3H]PK11195 was used as a radioligand to assess PBR kinetic parameters.

Main Results:

  • fMLP stimulation significantly decreased Kd and Bmax in neutrophil membranes.
  • Neutrophil membranes from psoriatic arthritis patients showed increased PBR binding sites and affinity.
  • A modulation of [3H]PK11195 binding was observed in human neutrophils.

Conclusions:

  • fMLP stimulation influences [3H]PK11195 binding in human neutrophils.
  • Psoriatic arthritis is associated with an up-regulation of PBR in neutrophils.
  • PBR may serve as a biomarker for psoriatic arthritis.

Related Concept Videos